News: Aegerion Pharmaceuticals Inc (AEGR.O)
58.25USD
22 May 2013
$-1.77 (-2.95%)
$60.02
$60.00
$61.93
$57.06
768,725
632,420
$63.72
$12.86
Mon, Dec 24 2012
FDA approves Aegerion's cholesterol drug with strongest warning
- Aegerion Pharmaceuticals Inc said the U.S. health regulator approved its drug as an alternative treatment for patients who have a genetic predisposition to high cholesterol.
- Aegerion's Pricing Power Sends Shares Flying
- Insiders And Funds Are Bullish On These 3 Small Cap Healthcare Stocks
- Too Many Questions Make This Thursday Mover a Sell
- 3 Humongous Health-Care Stocks This Week
- 4 Companies With Extreme Price Charts And High Statistical Probability Of Decline
- 3 Stocks Near 52-Week Highs Worth Selling
Press Releases
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
- Aegerion Pharmaceuticals Announces Presentation at the Bank of America Merrill Lynch 2013 Healthcare Conference
- Aegerion Pharmaceuticals Announces First-Quarter 2013 Financial Results
- Anne VanLent Appointed to Aegerion Pharmaceuticals' Board of Directors
- Aegerion Pharmaceuticals Announces Presentation at the Needham Healthcare Conference
- Aegerion Pharmaceuticals to Announce First Quarter 2013 Financial Results on Tuesday, April 30
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
- A forward Look into the Year Ahead - Research Report on Boyd Gaming Corporation, Ameristar Casinos, Inc., Aegerion Pharmaceuticals, Inc., ISIS Pharmaceuticals, Inc. and Avon Products, Inc.
- Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
